Rituxan Launch For Arthritis, Tysabri Return Expected In Mid-’06, Biogen Says
Executive Summary
Biogen Idec could launch Rituxan (rituximab) for rheumatoid arthritis and relaunch Tysabri (natalizumab) for multiple sclerosis by mid-2006, CFO Peter Kellogg said during an Oct. 26 earnings call
You may also be interested in...
Rituxan RA Approval Raises The Stakes, But With A Lower Price
Genentech/Biogen Idec are pricing Rituxan (rituximab) for rheumatoid arthritis at a lower cost for most patients than the closest comparable biologic, Bristol-Myers Squibb's Orencia (abatacept)
Rituxan RA Approval Raises The Stakes, But With A Lower Price
Genentech/Biogen Idec are pricing Rituxan (rituximab) for rheumatoid arthritis at a lower cost for most patients than the closest comparable biologic, Bristol-Myers Squibb's Orencia (abatacept)
Tysabri Safety Study To Commence Following Lift Of Clinical Hold
Biogen Idec/Elan's monotherapy safety extension study of its multiple sclerosis therapy Tysabri will help shape FDA's risk management demands for the biologic, assuming it is re-approved